Collegium Pharmaceutical (COLL) Competitors $38.41 -0.65 (-1.66%) As of 11:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock COLL vs. PTCT, KRYS, PCVX, ACAD, ACLX, ADMA, ARWR, MENS, MIRM, and MLTXShould you be buying Collegium Pharmaceutical stock or one of its competitors? The main competitors of Collegium Pharmaceutical include PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Vaxcyte (PCVX), ACADIA Pharmaceuticals (ACAD), Arcellx (ACLX), ADMA Biologics (ADMA), Arrowhead Pharmaceuticals (ARWR), Jyong Biotech (MENS), Mirum Pharmaceuticals (MIRM), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. Collegium Pharmaceutical vs. Its Competitors PTC Therapeutics Krystal Biotech Vaxcyte ACADIA Pharmaceuticals Arcellx ADMA Biologics Arrowhead Pharmaceuticals Jyong Biotech Mirum Pharmaceuticals MoonLake Immunotherapeutics PTC Therapeutics (NASDAQ:PTCT) and Collegium Pharmaceutical (NASDAQ:COLL) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings. Do analysts rate PTCT or COLL? PTC Therapeutics currently has a consensus target price of $69.00, suggesting a potential upside of 13.75%. Collegium Pharmaceutical has a consensus target price of $42.33, suggesting a potential upside of 10.21%. Given PTC Therapeutics' higher possible upside, equities research analysts clearly believe PTC Therapeutics is more favorable than Collegium Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PTC Therapeutics 1 Sell rating(s) 5 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.53Collegium Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is PTCT or COLL more profitable? PTC Therapeutics has a net margin of 35.65% compared to Collegium Pharmaceutical's net margin of 5.13%. Collegium Pharmaceutical's return on equity of 97.28% beat PTC Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PTC Therapeutics35.65% -106.31% 30.61% Collegium Pharmaceutical 5.13%97.28%13.87% Does the media refer more to PTCT or COLL? In the previous week, PTC Therapeutics had 13 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 17 mentions for PTC Therapeutics and 4 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 1.60 beat PTC Therapeutics' score of 0.92 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Collegium Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more risk & volatility, PTCT or COLL? PTC Therapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Which has higher earnings & valuation, PTCT or COLL? Collegium Pharmaceutical has lower revenue, but higher earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPTC Therapeutics$806.78M5.97-$363.30M$6.978.70Collegium Pharmaceutical$631.45M1.92$69.19M$1.0436.93 SummaryPTC Therapeutics beats Collegium Pharmaceutical on 8 of the 15 factors compared between the two stocks. Get Collegium Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COLL vs. The Competition Export to ExcelMetricCollegium PharmaceuticalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.21B$2.55B$5.80B$10.16BDividend YieldN/A56.65%5.69%4.61%P/E Ratio36.8623.4774.7325.99Price / Sales1.92554.82470.3491.76Price / Cash3.05169.2537.0859.91Price / Book5.415.3712.256.31Net Income$69.19M$32.95M$3.28B$270.66M7 Day Performance0.23%2.18%1.39%3.52%1 Month Performance1.43%9.45%7.70%6.79%1 Year Performance5.15%1.25%64.01%28.29% Collegium Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COLLCollegium Pharmaceutical3.5233 of 5 stars$38.41-1.7%$42.33+10.2%+7.9%$1.21B$631.45M36.86210Positive NewsPTCTPTC Therapeutics3.6468 of 5 stars$56.95-0.5%$69.00+21.2%+88.9%$4.55B$806.78M8.171,410Insider TradeKRYSKrystal Biotech4.942 of 5 stars$145.20-3.4%$210.38+44.9%-27.4%$4.35B$290.52M29.51210Positive NewsPCVXVaxcyte2.2918 of 5 stars$32.41-1.8%$130.00+301.1%-70.9%$4.29BN/A-7.89160Positive NewsAnalyst ForecastACADACADIA Pharmaceuticals4.3958 of 5 stars$25.39+0.5%$28.88+13.7%+51.7%$4.26B$957.80M19.09510Positive NewsAnalyst ForecastACLXArcellx2.2443 of 5 stars$71.11-2.1%$114.31+60.7%+4.4%$4.03B$107.94M-20.7980Positive NewsADMAADMA Biologics3.7357 of 5 stars$16.42-2.7%$27.67+68.5%-4.7%$4.03B$426.45M19.09530Positive NewsARWRArrowhead Pharmaceuticals4.1574 of 5 stars$27.17-6.6%$43.14+58.8%+41.9%$4.02B$3.55M-21.23400Analyst RevisionMENSJyong BiotechN/A$55.68+6.4%N/AN/A$3.98BN/A0.0031News CoverageGap DownHigh Trading VolumeMIRMMirum Pharmaceuticals3.2009 of 5 stars$77.39+1.7%$74.13-4.2%+81.3%$3.82B$336.89M-63.96140Analyst ForecastMLTXMoonLake Immunotherapeutics2.5283 of 5 stars$61.12+2.8%$74.43+21.8%+17.0%$3.82BN/A-21.992Positive News Related Companies and Tools Related Companies PTCT Competitors KRYS Competitors PCVX Competitors ACAD Competitors ACLX Competitors ADMA Competitors ARWR Competitors MENS Competitors MIRM Competitors MLTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COLL) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredNVDA: The cracks are beginning to showThe media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. I...InvestorPlace | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collegium Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
